The TRUST Study - Depression Substudy

PHASE4CompletedINTERVENTIONAL
Enrollment

426

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

April 5, 2018

Study Completion Date

April 5, 2018

Conditions
Subclinical HypothyroidismDepression
Interventions
DRUG

Levothyroxine

The intervention will start with Levothyroxine 50 µg daily (reduced to 25 µg in subjects \<50Kg body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) versus matching placebo; at 3 months if the serum TSH level is \<0.4 mU/L dose will be reduced by 25 µg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6mUL, additional 25 µg. The process will be repeated at 12 months then annually. Mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine that will be prescribed is 150μg (after 4 increments of 25μg at 3 months, 1, 2 and 3 years; from the starting dose of 50μg).

DRUG

Placebo

"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."

Trial Locations (3)

1011

Department of General Internal Medicine, Lausanne

2300

Leiden University Medical Center, Leiden

3010

University Clinic for General Internal Medicine, Bern University Hospital, Bern

All Listed Sponsors
collaborator

Leiden University Medical Center

OTHER

collaborator

University of Bern

OTHER

lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT01853579 - The TRUST Study - Depression Substudy | Biotech Hunter | Biotech Hunter